Last reviewed · How we verify

NCT00663780

Pharmacogenomic Analysis of Blood Samples to Identify Polymorphisms That Segregate Responders From Non-Responders Following Treatment With Juvidex of Split Skin Donor Sites in Renovo's Clinical Study RN1004-0082

Completed Last updated 5 January 2009
What this trial tests

trial in Wound in 195 participants. Completed in 1 September 2008.

Timeline
1 February 2008
Primary endpoint
1 September 2008
1 September 2008

Quick facts

Lead sponsorRenovo
StatusCompleted
Study typeOBSERVATIONAL
Enrollment195
Start date1 February 2008
Primary completion1 September 2008
Estimated completion1 September 2008
Sites1 location across United Kingdom

Conditions studied

Sponsor

Renovo — full company profile →

Who can join

Adults 18 to 85, any sex, with Wound. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The objective of the study is to identify variations in subjects genetic makeup that segregate responders from non-responders in respect of response to Juvidex in the clinical trial RN1004-0082

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Wound

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00663780.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing